ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1082

Association Between Level of Physical Activity and Cognition in CKD (PAC-CKD): A UK Biobank Study

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1500 Health Maintenance, Nutrition, and Metabolism

Authors

  • Ryan, Louise A., University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Dasgupta, Indranil, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background

Cognitive function (CF) declines steadily with advancing CKD and affects up to 80% of people with end-stage kidney disease. Physical activity (PA) reduces the risk of cognitive impairment in the general population. We aimed to assess the association of PA with CF in adults with CKD using the UK Biobank data.

Methods

CF was assessed by a composite of fluid intelligence, numeric memory (NM) and reaction time tests. CKD was classified into stages 1-5 and "No CKD" based on eGFR and albumin creatinine ratio. PA was measured by the International Physical Activity Questionnaire and classified into high, moderate and low PA levels. Multilinear regression was performed, with the Cohen’s d, with the No CKD group as reference, reported. A Wald test was used to test the interaction of CKD stage and PA on cognitive function.

Results

Of the 501,520 participants, 692, 749, 7389, 299 and 51 had CKD stages 1-5 respectively. The median ages for no CKD and CKD stages 1 to 5 were 58, 55, 62, 65, 65, and 62 respectively. Diabetes rates were 5.4%, 23.7%, 31.4%, 21.9%, 40.8%, and 49% and hypertension rates were 26.2%, 46.1%, 68.9%, 69.3%, 83.3%, and 86.3% respectively. The percentage of participants in the high and moderate PA groups were 39.7 and 40.1 for Stage 1, 34.8 and 40.7 for Stage 2, 33.7 and 40.6 for Stage 3, 23.4 and 43.8 for Stage 4, 15.7 and 37.3 for stage 5 and 40.7 and 41.5 for those without CKD.
After adjustment for age, education and comorbidities, cognitive scores decreased with advancing CKD (table 1). Apart from NM in Stage 5 CKD, where high PA negatively affected CF, these associations did not significantly differ by PA level.

Conclusion

The decline in cognitive function with advancing CKD did not significantly differ by PA apart from NM in Stage 5, where the number was small.

Digital Object Identifier (DOI)